Dateline City:
WHITEHOUSE STATION, N.J.
Data to be Presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced data for its investigational Timothy grass sublingual
allergy immunotherapy tablet (MK-7243) from a study involving 1,501
North American adult and pediatric patients.
Language:
English
Contact:
For MerckMedia:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more